At present, the main therapies aimed at slowing down the progression of DKD involve blood pressure lowering, intensive glucose control, and blood lipid regulation, with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) serving as the cornerstone of DKD management (8). The gene discussed is ACE; the disease is diabetic kidney disease.